Sociedad Americana de Hirudoterapia

Head and neck microvascular free flap reconstruction: An analysis of unplanned readmissions.

Research article published in The Laryngoscope (2016)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Observational studyEnsayos clínicosCarniol et al. · The Laryngoscope, 2016

Abstract

OBJECTIVES/HYPOTHESIS: Unplanned readmissions within 30 days of surgery represent a significant marker for healthcare quality. Small institutional studies have described rates of readmission for patients undergoing head and neck free flap reconstruction. However, large, multi-institutional analyses have not previously been described. STUDY DESIGN: Retrospective study of cases from the American College of Surgeons National Surgical Quality Improvement Program database. METHODS: Patients who underwent free flap reconstruction of the head and neck from 2011 to 2013 were identified. Univariate and multivariate analyses of unplanned readmission based on patient, laboratory, and hospital course characteristics were conducted. RESULTS: In total, 1,238 patients who underwent head and neck microvascular free flap reconstruction were included within the database, of which 1,204 patients had information pertaining to readmission. Overall 30-day readmission rate was 9.6%. A multivariate analysis of preoperative variables demonstrated that leukocytosis, diabetes mellitus, and hyponatremia were all associated with increased rates of readmission (odds ratio 2.224, 1.843, and 1.7423, respectively). A similar analysis of postoperative variables demonstrated that wound-related complications (surgical site infections and wound disruption), perioperative blood transfusion, and sepsis were associated with an increased rate of readmission. CONCLUSION: In patients with microvascular free flap reconstruction of the head and neck, the 30-day readmission rate was 9.6%. Preoperative diabetes mellitus, hyponatremia, and leukocytosis were associated with an increased rate of 30-day readmissions. Postoperative complications, particularly wound infections, perioperative blood transfusions, and sepsis, were found to be significant contributors to readmission. LEVEL OF EVIDENCE: 4. Laryngoscope, 2016 127:325-330, 2017.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMulticenter Study
Indexed MeSH termsAdultAgedAged, 80 and overCross-Sectional StudiesFemaleFollow-Up StudiesFree Tissue FlapsHumansMaleMicrosurgeryMiddle AgedOtorhinolaryngologic Neoplasms

Resumen

Unplanned readmissions within 30 days of surgery represent a significant marker for healthcare quality. Small institutional studies have described rates of readmission for patients undergoing head and neck free flap reconstruction.

Por qué esto importa para la hirudoterapia

Este estudio analizó los reingresos no planificados a 30 días tras la reconstrucción microvascular con colgajo libre de cabeza y cuello utilizando datos de 1.238 pacientes de la base de datos del Programa Nacional de Mejora de la Calidad Quirúrgica del Colegio Americano de Cirujanos (2011–2013), informando una tasa global de reingreso a 30 días del 9,6 %. Los análisis multivariantes identificaron leucocitosis preoperatoria, diabetes mellitus e hiponatremia, así como complicaciones postoperatorias relacionadas con la herida, transfusión sanguínea perioperatoria y sepsis como contribuyentes significativos al reingreso. El resumen no menciona sanguijuelas, hirudoterapia, congestión venosa ni ninguna conexión con el secretoma de la sanguijuela. No existe un vínculo defendible con las sanguijuelas en este artículo.

Citación

Head and neck microvascular free flap reconstruction: An analysis of unplanned readmissions.

Carniol et al. · The Laryngoscope, 2016

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.